Peggy Scherle, Chief Scientific Officer at Prelude Therapeutics Inc (PRLD), sold 20,000 shares at $35.45 ($709K) on 2021-07-27, disclosed to the SEC on 2021-07-29.
Open-market sale of $709k PRLD by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $35.45 | 19,320 | $685K | 96.5% |
| 2 | $36.09 | 680 | $25K | 3.5% |
| Total | $35.47 avg | 20,000 | $709K | 100% |
| Filing → |
| PRLD | SELL | 2021-05-11 | $808K | — | Filing → |
| PRLD | SELL | 2021-04-15 | $296K | — | Filing → |
| PRLD | SELL | 2021-04-09 | $1.2M | — | Filing → |